Under the terms of the agreement, the parties intend to make the new Potelligent CHOK1SV cell line available for licensing and it will be offered as part of Lonza’s development services in combination with Lonza’s GS gene expression system. This is expected to generate a new technology platform to produce more potent antibodies with greatly enhanced antibody-dependent cellular cytotoxicity (ADCC) in a high-yield mammalian expression system for industry-wide use. The two companies will jointly market the new technology platform.
Masamichi Koike, president and CEO of BioWa, said: “We believe that combining both parties’ technologies addresses a clear market need to improve production yields and can significantly aid the development of more effective targeted treatments for cancer and other life-threatening and debilitating diseases.”